MX2007004020A - Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica. - Google Patents

Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.

Info

Publication number
MX2007004020A
MX2007004020A MX2007004020A MX2007004020A MX2007004020A MX 2007004020 A MX2007004020 A MX 2007004020A MX 2007004020 A MX2007004020 A MX 2007004020A MX 2007004020 A MX2007004020 A MX 2007004020A MX 2007004020 A MX2007004020 A MX 2007004020A
Authority
MX
Mexico
Prior art keywords
diastolic
prevention
treatment
heart failure
renin inhibitors
Prior art date
Application number
MX2007004020A
Other languages
English (en)
Inventor
Randy Lee Webb
David Louis Feldman
Friedrich Cameron Luft
Dominik Nicolas Mueller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007004020(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007004020A publication Critical patent/MX2007004020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona el uso de una cantidad terapeuticamente efectiva de un inhibidor de renina, o sal farmaceuticamente aceptable del mismo, solo o en combinacion con (i) un inhibidor de ACE o una sal farmaceuticamente aceptable del mismo; o (ii) un bloqueador de receptor de angiotensina II o una sal farmaceuticamente aceptable del mismo, para la fabricacion de un medicamento para la prevencion de, progresion retardada para que se manifieste, o el tratamiento de disfuncion diastolica o falla cardiaca diastolica en un animal de sangre caliente.
MX2007004020A 2004-10-08 2005-10-06 Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica. MX2007004020A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61720204P 2004-10-08 2004-10-08
US66789905P 2005-04-01 2005-04-01
PCT/US2005/035914 WO2006041974A1 (en) 2004-10-08 2005-10-06 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure

Publications (1)

Publication Number Publication Date
MX2007004020A true MX2007004020A (es) 2007-05-24

Family

ID=35789048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004020A MX2007004020A (es) 2004-10-08 2005-10-06 Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.

Country Status (15)

Country Link
US (2) US20080085914A1 (es)
EP (2) EP2248520A3 (es)
JP (1) JP2008515903A (es)
KR (2) KR20070101843A (es)
CN (1) CN101102755B (es)
AT (1) ATE551052T1 (es)
AU (2) AU2005294318A1 (es)
BR (1) BRPI0516128A (es)
CA (1) CA2580862A1 (es)
ES (1) ES2384637T3 (es)
MX (1) MX2007004020A (es)
PL (1) PL1799199T3 (es)
PT (1) PT1799199E (es)
RU (1) RU2407523C2 (es)
WO (1) WO2006041974A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
EP2138184B1 (en) 2007-03-27 2013-09-18 Calpis Co., Ltd. Tripeptides for use in preventing kidney glomerular disease
WO2009045795A2 (en) * 2007-09-28 2009-04-09 Novartis Ag Galenical formulations of aliskiren and valsartan
RU2010116526A (ru) * 2007-09-28 2011-11-10 Новартис АГ (CH) Фармацевтическая комбинация алискирена и валсартана
EP2391345B1 (en) * 2009-01-28 2014-09-03 Novartis AG Galenic formulations comprising aliskiren
EP2216020A1 (en) * 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EA201190091A1 (ru) * 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
EP2340820A1 (en) * 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
US20110268797A1 (en) * 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0955294B1 (en) 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazolyl-alkenoic acid
DE19675036I2 (de) 1990-02-19 2004-10-21 Novartis Ag Acylverbindungen.
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
HU227346B1 (en) * 1990-05-11 2011-04-28 Pfizer Process for producing synergetic pharmaceutical composition
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
TW226375B (es) 1991-10-24 1994-07-11 American Home Prod
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1353727A2 (en) * 2000-12-01 2003-10-22 Novartis AG Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
WO2004002549A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
DE602004022704D1 (de) * 2003-11-26 2009-10-01 Novartis Ag 4-phenylpiperidinderivate als renininhibitoren
CN102260188A (zh) * 2003-11-26 2011-11-30 诺瓦提斯公司 有机化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
EP1799199A1 (en) 2007-06-27
PT1799199E (pt) 2012-07-03
CN101102755A (zh) 2008-01-09
AU2005294318A1 (en) 2006-04-20
US20080085914A1 (en) 2008-04-10
WO2006041974A1 (en) 2006-04-20
KR20070101843A (ko) 2007-10-17
BRPI0516128A (pt) 2008-08-26
EP2248520A2 (en) 2010-11-10
AU2010200833B2 (en) 2011-07-14
AU2010200833A1 (en) 2010-04-01
RU2407523C2 (ru) 2010-12-27
EP1799199B1 (en) 2012-03-28
ES2384637T3 (es) 2012-07-10
CN101102755B (zh) 2013-01-02
RU2007116863A (ru) 2008-11-20
EP2248520A3 (en) 2010-11-17
CA2580862A1 (en) 2006-04-20
JP2008515903A (ja) 2008-05-15
US20130196977A1 (en) 2013-08-01
PL1799199T3 (pl) 2012-09-28
KR20130048281A (ko) 2013-05-09
ATE551052T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
MX2007004020A (es) Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
TNSN07312A1 (en) Combination of organic compounds
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2007149797A3 (en) Use of organic compounds
WO2007019153A3 (en) Methods for treating hypertension
TW200602022A (en) Use of PDE III inhibitor for the reduction of heart size in mammals suffering from heart failure
DE60329001D1 (en) 8-hydroxychinolinderivate
MX2009004984A (es) Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
WO2001076573A3 (en) Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
MX346186B (es) Inhibidores de proteina cinasas.
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
ZA200806778B (en) N-Hydroxyacrylamide compounds
EP3276004A3 (en) Methods for treating chronic kidney disease
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
TW200742580A (en) Methods for treating nephrolithiasis
TW200806283A (en) Therapeutic methods
TW200621248A (en) Drug for glomerular diseases
UA107716C2 (ru) Терапевтическое средство с замедленным высвобождением на основе соединения 2-фенилтиазола для гипертонии и почечной дисфункции
MX2009006340A (es) Metodos terapeuticos.
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors
WO2007120669A8 (en) Tetrahalogenated compounds useful as inhibitors of angiogenesis

Legal Events

Date Code Title Description
FG Grant or registration